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Abstract This report describes the quasi-simultaneous
occurrence of colon cancers in monozygotic twin brothers
(age 63 years) who had undergone androgen deprivation
therapy for prostate cancers 4 years earlier. Concordance
among male twins for both of these cancers has never been
reported. Although the family history suggested possible
genetic predispositions to both cancers, the twins have no
evidence of the genetic alterations associated with heredi-
tary colorectal tumors. We explore the possibility that
colorectal tumorigenesis in these twins was fuelled by a
combination of genetic and iatrogenic factors, in particular
the androgen deprivation therapy used to treat their prostate
cancers.
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Introduction
Prostate and colorectal cancers are common in western
populations. The epidemiology of these diseases suggests
that, in a substantial proportion of cases, genetic factors play
a role [1–3]. Twin studies have been used to estimate the
relative contributions of inherited genetic alterations and
environmental factors to the development of these two
cancers [4–8]. The dizygotic twin brothers of men with
prostate cancer have a relative risk for developing this
cancer of around three, but this figure is four times higher for
monozygotic twins [1]. Indeed, probandwise concordance
rates reported for prostate cancer are around 5% in dizygotic
twins and approximately 20% in those who are monozygotic
[1, 7, 8]. Men whose twin brothers have colorectal cancer are
also more likely to develop this cancer. In this case, how-
ever, the relative risk for a monozygotic twin (around seven)
is decidedly lower than that described for prostate cancer
and similar to that of his dizygotic counterpart (around six).
Colon cancer concordance rates (8 and 9% in dizygotic and
monozygotic male twins) are also unrelated to zygosity [1].
These figures suggest that, while predisposing genetic
factors contribute to the development of both prostate and
colorectal cancer, nongenetic factors play a more sub-
stantial role in the latter disease. This conclusion appears to
be strongly supported by the clinical and molecular evi-
dence we collected on a pair of monozygotic twins who
developed adenocarcinomas of the prostate and 4 years
later adenocarcinomas of the colon. Genetic testing has
excluded the presence of mutations currently known to
cause predisposition to colorectal cancer. We explore the
possibility that the development of their colon tumors
might have been triggered by a combination of shared
genetic and nongenetic factors, the latter including the
treatment they received for their prostate cancers.
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Patients and procedures
Patients 1 and 2 were male monozygotic twins of Cauca-
sian origin. (Monozygosity was confirmed [probability:
99.96%] by the analysis of nine autosomal STR (short
tandem repeat) markers.) Neither was married. They
worked together in the same office, shared an apartment,
had similar diets and normal body mass indexes, and both
were smokers.
In October 1997, patient 1 (subject III-1 in Fig. 1), then
58 years old, underwent transurethral resection for what
proved to be prostate cancer (T3-4N0M0 based on imaging
data; Gleason score 7 [3 ? 4]). He received 3 months of
percutaneous radiotherapy with neoadjuvant and adjuvant
androgen ablation therapy based on goserelin and bicalu-
tamide (details in Fig. 2). Three years later (June 2001),
the cancer recurred with bone and biopsy-confirmed liver
metastases. Goserelin treatment was resumed, and inter-
mittent chemotherapy with docetaxel was then given for
several months.
In March 2002, the patient was completely asymptom-
atic, but computed tomography performed for therapy
control revealed a suspicious lesion in the sigmoid
colon. Colonoscopy disclosed a sigmoid adenocarcinoma
(2.7 9 2.5 cm) and a severely dysplastic tubular adenoma
(5.5 9 4.3 cm) in the ascending colon. The tumors were
removed by anterior colonic resection and partial resection
of the ascending colon, and the colon cancer was classified
as pT3pN0M0, G3. Nine months after surgery (January
2003), colonoscopy was repeated to determine the cause of
the patient’s persistent diarrhea, and nine new adenomas
(tubular or tubulo-villous, diameters, 2–20 mm) were
removed. These lesions varied in terms of the degree of
dysplasia, and one polyp located in the right flexure proved
to be a well-differentiated, stage I adenocarcinoma.
Since June 2001, the patient’s metastatic prostate cancer
had been controlled with docetaxel, but in March 2003 new
liver metastases appeared, and prostate-specific antigen
(PSA) levels rose. Repeat colonoscopy revealed two new
tubular adenomas (diameters, 3 mm) that were promptly
removed. The patient was still receiving goserelin (Fig. 2),
and experimental capecitabine therapy was started, but in
June 2003—69 months after the prostate cancer had been
diagnosed, 14 months after the diagnosis of colon cancer—
the patient died of progressive prostate cancer (verified by
autopsy).
Patient 2’s prostate cancer (T1cN0M0; Gleason score
6 [3 ? 3]) was diagnosed in February 1998 (4 months
after the discovery of his twin’s tumor—Fig. 2) as a result
of PSA-based screening and ultrasound-guided needle
biopsy. Like his brother, patient 2 (III-2 in Fig. 1) received
percutaneous radiotherapy and dual-agent androgen-
deprivation therapy (Fig. 2). In May 2002, when his
brother’s colon cancer was diagnosed, he had a colonos-
copy (although he was completely asymptomatic), which
revealed a cecal carcinoma (3.5 9 2.8 cm) and three
metachronous tubular and tubulo-villous adenomas of the
proximal colon (diameters 5–20 mm). These lesions were
eliminated with a right hemicolectomy, and the colon
cancer was classified as pT2pN0M0, G2-3. Colonoscopy
was repeated postoperatively to remove six small polyps
(diameters 2–5 mm), including a 5 mm tubular adenoma.
Because of his brother’s history, patient 2 received close
endoscopic follow-up. Eight months after his hemicolec-
tomy (January 2003), a tubular adenoma was removed
from the sigmoid colon. Since then over ten hyperplastic
polyps have been removed from various parts of the
remaining colon. In September 2007, PSA levels rose, but
the patient is currently completely asymptomatic without
treatment.
Genetic testing
Prostate and colorectal cancers are both common in the
general population, so we cannot exclude the possibility
that the cancers diagnosed in these twins are phenocopies.
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Fig. 1 Pedigree of the twins’
family. Circles represent
females; squares stand for
males. Slashes indicate
deceased family members. Gray
symbols represent individuals
who developed cancer (site and
age at onset specified below the
symbol). When the pedigree
was created, patient 1 (III-1)
had died, patient 2 (III-2) was
69 years old, and their only
living relatives (III-3 and III-4)
were asymptomatic and refused
to be screened for colon cancer
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However, their family history was suggestive of a genetic
cancer predisposition (Fig. 1). Although the cancer aggre-
gation pattern was not indicative of any of the well-known
cancer predisposition syndromes, we assessed the brothers’
cancers for microsatellite instability, a hallmark of the
mismatch repair deficiency that leads to the hereditary non-
polyposis colon cancer syndrome. Defective mismatch
repair was excluded by the absence of instability at three
sensitive microsatellite markers (BAT25, BAT26, BAT40)
and by immunohistochemical studies showing normal
expression in the tumors of five mismatch repair proteins
(MLH1, PMS2, MSH2, MSH6, and MSH3). The tumors
also displayed normal immunohistochemical labelling for
the cell-cycle checkpoint factor CHEK2. (Alterations of the
gene that encodes this protein are reportedly associated
with increased rates of both prostate and colon cancer [9].)
Since both men had presented multiple colon adenomas,
they were also tested for germline mutations involving the
adenomatous polyposis coli gene (the protein truncation
test); the MutY homolog (MUTYH) gene (denaturing high-
performance liquid chromatography and direct sequenc-
ing); and the tumor suppressor p53 (TP53) gene (direct
sequencing of exons 5–8), but no pathogenic alterations
were detected.
Discussion
These monozygotic twins were 58 years old when they
were diagnosed with prostate cancer. Patient 1’s tumor was
advanced (T3-4, Gleason score 7) at the time of diagnosis,
and his father had had the same type of cancer at age 66.
Consequently, PSA-based screening was suggested for his
twin brother, who was completely asymptomatic, and this
precaution led to the diagnosis of an early-stage prostate
cancer (T1c, Gleason score 6). Both men underwent per-
cutaneous radiotherapy and dual-agent androgen
deprivation (Fig. 2). Four years later the twins were found
to have colon cancers as well. Again, patient 1’s tumor was
detected first, and its discovery led his twin to undergo
colonoscopic screening, which revealed an earlier stage
malignant neoplasm in the cecum.
Cancers of the prostate and colon are among the most
common forms of neoplastic disease in Western men, and
both are known to be caused in part by hereditary factors.
The Swedish Twin Registry is one of the most informative
registries of this type in the world [10]. It contains data on
over 29,000 pairs of male twins, including eight cases (five
monozygotic pairs, three dizygotic pairs) in which one twin
has prostate and colon cancers, and the second has prostate
Patient 1 (III-1)
Oct 1997            Diagnosis of prostate adenocarcinoma
(T34N0M0, Gleason 7 [3+4])
Nov 1997 Androgen deprivation with goserelin
May 1998 and bicalutamide 
FebApr 1998      Percutaneous radiotherapy (74 Gy)
June 2001 Prostate cancer metastases to liver
and bone. Androgen deprivation with
goserelin resumed ; intermittent 
chemotherapy with  docetaxel given
through March 2003
Mar 2002 Diagnosis and surgical removal of a
sigmoid adenocarcinoma 
(pT3pN0M0, G3)
Jan 2003 Diagnosis and removal of 2nd
adenocarcinoma of the colon (pT1)
and 9 metachronous adenomas
(tubular or tubulovillous)
Mar 2003 Progressive prostate cancer (increase
of PSA and new liver metastases ).
Goserelin continued ;  capecitabine 
started.
Mar 2003 Two new colon adenomas removed
June 2003 Death from progressive prostate
cancer
Patient 2 (III-2)
Feb 1998            Diagnosis of prostate adenocarcinoma
(T1cN0M0, Gleason 6 [3+3])
MarAug 1998 Androgen deprivation with goserelin
and bicalutamide
MayJun 1998 Percutaneous radiotherapy (72 Gy)
May 2002 Diagnosis and surgical removal of a
cecal adenocarcinoma (pT2pN0M0,
G23) and 3 proximal colon
adenomas. Endoscopic removal of
6 additional small adenomas
Jan 2003 Endoscopic removal of 11
present      metachronous colon polyps (1
adenomatous and 10 hyperplastic ) 
Sept 2007 Biochemical recurrence of prostate 
cancer
Fig. 2 Overview of the twins’
clinical histories. Immediately
after the diagnosis of prostate
cancer, both patients received
percutaneous radiotherapy with
neoadjuvant and adjuvant
androgen deprivation therapy
based on goserelin (10.8 mg
every 3 months) with
bicalutamide (50 mg daily for
2 weeks before and 2 weeks
after the first goserelin
injection) to prevent
testosterone flare-ups, as well as
percutaneous radiotherapy.
When Patient 1 developed
metastatic disease, he received
goserelin (at the original
dosage; continued until his
death in 2003) and docetaxel
(35 mg per square meter of
body surface area every
4 weeks [on days 1, 8, and 15]
for several months). During the
last 3 months he also received
experimental treatment with
capecitabine
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or colon cancer. But there is not one case in which colon
and prostate cancers have been found in both twins (P.
Lichtenstein, pers. comm.).
Concordance rates for prostate cancer among monozy-
gotic male twins (20%) are markedly higher than those
observed among their dizygotic counterparts (5%) [1, 7, 8]
a pattern that is indicative of a substantial heritable com-
ponent in this type of cancer. However, identification of the
genetic alteration(s) that predispose a patient to this type of
disease is currently a complicated process, and the results
are far from conclusive. A few genetic loci have displayed
associations with prostate cancer susceptibility in linkage
analyses [11], but in some cases, the association is based
solely on the analysis of a few kindreds. In others, causa-
tive roles have not been confirmed in subsequent studies.
Very recently, certain common gene variants have been
reported to increase the risk of prostate cancer [12], but the
list of variants and their combinations will probably be
refined in future genome-wide association studies and
prospective trials. For these reasons, we have not attempted
thus far to identify genetic alteration(s) that might have
predisposed these two men to prostate cancer.
Indeed, our primary objective has been to characterize
the twins’ colon-cancer concordance, where the role played
by genetic factors is even harder to pinpoint. In both cases,
the cancers were associated with multiple synchronous and
metachronous colon adenomas, which were suggestive of
an inherited predisposition to this type of neoplasia, and
two of the brothers’ second-degree relatives had died of
colon cancer (Fig. 1). However, the results of genetic
testing have excluded the principal inherited causes of
elevated colon cancer risk, including the classic and
attenuated forms of familial adenomatous polyposis and
the hereditary nonpolyposis colon cancer syndrome [3, 13].
The possibilities of inheritable changes in the multiorgan
cancer susceptibility gene CHEK2 [9] or in the mutational
hotspot region of TP53 have also been ruled out.
These twins were also exposed to the same environ-
mental risk factors for cancer, including those related to
diet and smoking habits. The importance of shared non-
genetic factors in colon cancer concordance among twins is
reflected in the similar relative risks observed among the
mono- and dizygotic twin brothers of affected males. With
reference to their colon cancers, the fact that our patients
had received identical treatment for their prostate tumors
might be particularly relevant. The radiotherapy probably
played no significant role in the development or evolution
of the men’s multiple colorectal tumors. The cancer-con-
taining colon segments were not included in the treatment
volume nor were they located close to the portal fields of
irradiation. Moreover, the interval between the radiother-
apy and the development of colon cancer was also rather
short. A more interesting possibility is that the colon
tumors were somehow related to the dual-agent androgen
deprivation therapy that both men had received. Androgen
receptors are expressed in both healthy and neoplastic
colon tissues [14], and data from various studies suggest
that androgens exert protective effects in the colon [15–19].
For example, chemical castration has been shown to
enhance chemically induced colon carcinogenesis in rats
[19], and there is a large body of evidence indicating that
androgen-receptor activation in colon cancer cells can
repress canonical Wnt signalling (i.e., signalling through
the beta-catenin/TCF pathway) [20–22], which—in its
deregulated form—is believed to be responsible for the
vast majority of colorectal cancers—familial and sporadic
[23].
It is tempting to speculate that colon carcinogenesis in
these twins might have been fuelled—at least in part—by
iatrogenic androgen deprivation resulting in inappropriate
Wnt signalling. To our knowledge, the incidence of colon
tumors in subjects who receive androgen deprivation
therapy has never been specifically assessed in epidemi-
ological studies. It is possible that the impact of androgen
suppression on malignant transformation of the colon
mucosa is genetically influenced. In the patients described
here, this impact might have been increased by the genetic
factors that led to the development of prostate cancer, and
the fact that the two men were genetically identical may
have enhanced the visibility of an effect that has thus far
escaped notice in the general population. If so, identifi-
cation of these genetic factors could represent an
important step forward in our search for cancer suscepti-
bility loci.
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